Recombinant Human VEGF-B 167 Protein, CF Summary
Product Specifications
Pro22-Arg188
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
751-VEB
Formulation | Lyophilized from a 0.2 μm filtered solution in HCl with Trehalose. |
Reconstitution | Reconstitute at 250 μg/mL in 4mM HCl. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
When Recombinant Rat Neuropilin-1 Fc Chimera (Catalog # 566-N1) is immobilized at 1 µg/mL (100 µL/well) Recombinant VEGF-B 167 (Catalog # 751-VEB) binds with an ED50 of 10-80 ng/mL.
1 μg/lane of Recombinant Human VEGF-B 167 (Catalog # 751-VEB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing bands at 19-22 kD and 40-45 kDa, respectively..
Reconstitution Calculator
Background: VEGF-B
Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity (1, 2). Five mammalian members, including VEGF-A, -B, -C, -D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is co-expressed and can heterodimerize with VEGF (3). By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist (3, 4). The two VEGF-B isoforms have identical amino-terminal cysteine-knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGF R1), but not VEGF R2 or VEGF R3 (5). On endothelial cells, ligation of VEGF R1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin-1 (NP-1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP‑1 has been shown to bind PLGF-2, VEGF165 and VEGF R1 (6, 7). The many interactions of NP-1 with VEGF ligands and receptor suggests that NP-1 may function as a regulator of angiogenesis (7).
- Li, X. and U. Eriksson (2001) Int. J. Biochem Cell Biol. 33:421.
- Olofsson, B. et al. (1999) Curr. Opin. Biotechnol. 10:528.
- Olofsson, B. et al. (1996) Proc. Nat. Acad. Sci. USA 93:2576.
- Grimmond, S. et al. (1996) Benome Res. 6:124.
- Olofsson, B. et al. (1998) Proc. Nat. Acad. Sci. USA 95:11709.
- Makinen, T. et al. (1999) J. Biol. Chem. 274:21217.
- Fuh, G. et al. (2000) J. Biol. Chem. 275:26690.
Citations for Recombinant Human VEGF-B 167 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
An examination of the mechanisms driving the therapeutic effects of an AAV expressing a soluble variant of VEGF receptor-1
Authors: Moon, SY;Kim, HJ;Kim, JK;Kim, J;Choi, JS;Won, SY;Park, K;Lee, SHS;
PloS one
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA Capture -
An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma
Authors: Holm, A;Graus, MS;Wylie-Sears, J;Borgelt, L;Heng Tan, JW;Nasim, S;Chung, L;Jain, A;Sun, M;Sun, L;Brouillard, P;Lekwuttikarn, R;Kozakewich, H;Qi, JY;Teng, JC;Mulliken, JB;Vikkula, M;Francois, M;Bischoff, J;
bioRxiv : the preprint server for biology
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
LncRNA DANCR Enhances Angiogenesis to Promote Melanoma Progression Via Sponging miR-5194
Authors: Jia, J;Zhu, X;Xue, K;Huang, Y;Wu, M;Yang, Y;Liu, W;Zhang, H;He, L;Sun, H;
Journal of Cancer
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Systemic VEGF-A neutralization ameliorates diet-induced metabolic dysfunction.
Authors: Wu L, Meoli C, Mangiafico S, Fazakerley D, Cogger V, Mohamad M, Pant H, Kang M, Powter E, Burchfield J, Xirouchaki C, Mikolaizak A, Stockli J, Kolumam G, van Bruggen N, Gamble J, Le Couteur D, Cooney G, Andrikopoulos S, James D
Diabetes, 2014-04-02;63(8):2656-67.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Authors: Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST
Angiogenesis, 2010-10-16;13(4):337-47.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain.
Authors: Martino MM, Hubbell JA
FASEB J., 2010-07-29;24(12):4711-21.
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance -
Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Authors: Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV
Oncogene, 2010-03-08;29(20):2938-49.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.
Authors: Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S
J. Biol. Chem., 2008-10-15;283(49):34250-9.
Species: Human
Sample Types: N/A
Applications: ELISA (Standard) -
Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A.
Authors: Narazaki M, Tosato G
Blood, 2006-01-19;107(10):3892-901.
Applications: ELISA (Standard) -
Vascular endothelial growth factor-B promotes in vivo angiogenesis.
Authors: Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, Levy BI
Circ. Res., 2003-06-12;93(2):114-23.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human VEGF-B 167 Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Human VEGF-B 167 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by: